NEUBASE THERAPEUTICS INC (NBSE) Fundamental Analysis & Valuation

NASDAQ:NBSE • US64132K2015

Current stock price

0.378 USD
-0.01 (-3.2%)
At close:
0.42 USD
+0.04 (+11.11%)
After Hours:

This NBSE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NBSE Profitability Analysis

1.1 Basic Checks

  • In the past year NBSE has reported negative net income.
  • NBSE had a positive operating cash flow in the past year.
  • In the past 5 years NBSE always reported negative net income.
  • In the past 5 years NBSE always reported negative operating cash flow.
NBSE Yearly Net Income VS EBIT VS OCF VS FCFNBSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of NBSE (-73.74%) is worse than 69.40% of its industry peers.
  • NBSE has a Return On Equity of -150.22%. This is in the lower half of the industry: NBSE underperforms 65.98% of its industry peers.
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROIC N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
NBSE Yearly ROA, ROE, ROICNBSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

  • NBSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBSE Yearly Profit, Operating, Gross MarginsNBSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NBSE Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NBSE has more shares outstanding
  • NBSE has a better debt/assets ratio than last year.
NBSE Yearly Shares OutstandingNBSE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
NBSE Yearly Total Debt VS Total AssetsNBSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • NBSE has an Altman-Z score of -10.48. This is a bad value and indicates that NBSE is not financially healthy and even has some risk of bankruptcy.
  • NBSE has a worse Altman-Z score (-10.48) than 78.97% of its industry peers.
  • There is no outstanding debt for NBSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -10.48
ROIC/WACCN/A
WACCN/A
NBSE Yearly LT Debt VS Equity VS FCFNBSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 2.87 indicates that NBSE has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.87, NBSE is not doing good in the industry: 68.03% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.87 indicates that NBSE has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.87, NBSE is not doing good in the industry: 66.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
NBSE Yearly Current Assets VS Current LiabilitesNBSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NBSE Growth Analysis

3.1 Past

  • NBSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.05%, which is quite impressive.
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NBSE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.88% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBSE Yearly EPS VS EstimatesNBSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

2

4. NBSE Valuation Analysis

4.1 Price/Earnings Ratio

  • NBSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBSE Price Earnings VS Forward Price EarningsNBSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

  • 100.00% of the companies in the same industry are more expensive than NBSE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 0.1
EV/EBITDA N/A
NBSE Per share dataNBSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBSE's earnings are expected to grow with 21.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3Y21.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NBSE Dividend Analysis

5.1 Amount

  • No dividends for NBSE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NBSE Fundamentals: All Metrics, Ratios and Statistics

NEUBASE THERAPEUTICS INC

NASDAQ:NBSE (5/10/2024, 8:08:45 PM)

After market: 0.42 +0.04 (+11.11%)

0.378

-0.01 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13
Earnings (Next)08-12
Inst Owners3.64%
Inst Owner Change0%
Ins Owners12.28%
Ins Owner Change0%
Market Cap1.42M
Revenue(TTM)N/A
Net Income(TTM)-13.73M
Analysts43.33
Price Target142.8 (37677.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.15%
Min EPS beat(2)-2.3%
Max EPS beat(2)0%
EPS beat(4)2
Avg EPS beat(4)10.77%
Min EPS beat(4)-2.3%
Max EPS beat(4)30.42%
EPS beat(8)4
Avg EPS beat(8)4.45%
EPS beat(12)6
Avg EPS beat(12)1.88%
EPS beat(16)8
Avg EPS beat(16)-38.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 0.1
P/OCF 0.1
P/B 0.16
P/tB 0.16
EV/EBITDA N/A
EPS(TTM)-7.3
EYN/A
EPS(NY)-9.18
Fwd EYN/A
FCF(TTM)3.9
FCFY1032.8%
OCF(TTM)3.79
OCFY1003.88%
SpS0
BVpS2.44
TBVpS2.44
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr -683.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z -10.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)226.06%
Cap/Depr(5y)214.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y213.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y219.18%
OCF growth 3YN/A
OCF growth 5YN/A

NEUBASE THERAPEUTICS INC / NBSE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NEUBASE THERAPEUTICS INC (NBSE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NBSE.


What is the valuation status of NEUBASE THERAPEUTICS INC (NBSE) stock?

ChartMill assigns a valuation rating of 2 / 10 to NEUBASE THERAPEUTICS INC (NBSE). This can be considered as Overvalued.


What is the profitability of NBSE stock?

NEUBASE THERAPEUTICS INC (NBSE) has a profitability rating of 0 / 10.


How financially healthy is NEUBASE THERAPEUTICS INC?

The financial health rating of NEUBASE THERAPEUTICS INC (NBSE) is 5 / 10.